MDMA: Revenue from Supply, Value from IP

125 Views31 Jul 2026 07:21
Issuer-paid
PharmAla hit a commercial inflection in 3QFY26. Revenue of C$513,232 was up 3.8x Y/Y and nine-month revenue roughly tripled to C$1,000,256.
What is covered in the Full Insight:
  • Introduction to PharmAla and Recent Performance
  • Supply Chain Improvements and Fulfillment
  • Financial Strategy and Licensing Agreements
  • Regulatory Environment and Strategic Flexibility
  • Conclusion and Analyst Overview
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • MDMA: Revenue from Supply, Value from IP
    31 Jul 2026
x